Aker BioMarine ASA was recently informed that LYSOVETA, the company's innovative brain and eye health ingredient derived from krill, has received the necessary regulatory approval for commercial launch as a dietary supplement in the US. LYSOVETAtm is a dietary supplement featuring essential nutrients such as choline and Omega 3 in the form of Lysophosphatidylcholine (LPC). LPC is a molecule with the unique ability to be transported across the blood brain barrier containing important nutrients for the brain and eye health.

The company is working with well-established brands to drive commercial opportunities for LYSOVETAtm. Launching a new ingredient involves long processes, starting from client testing & trial and going all the way to retailer sales & marketing efforts, but the company has an ambition to have first sales of consumer products during 2024.